多参数磁共振成像在筛选有利风险2级组前列腺癌主动监测患者中的作用
该回顾性队列纳入2010至2019年接受根治性前列腺切除术的1117例有利风险2级组前列腺癌患者,评估术前多参数磁共振成像与不良病理的关联。阳性多参数磁共振成像与不良病理(OR 2.55,95%CI 1.75-3.40,p<0.0001)和升级(OR 3.89,95%CI 2.00-7.56,p<0.0001)风险升高相关,提示其可辅助筛选主动监测候选者。
要点
- 阳性多参数磁共振成像使有利风险2级组患者不良病理风险约翻倍(OR 2.55)。
- 阳性多参数磁共振成像与活检分级升级风险升高相关(OR 3.89)。
- 将多参数磁共振成像结果加入标准预测模型可提高决策曲线净获益。
核心结论
- 在有利风险2级组前列腺癌根治性切除标本中,多参数磁共振成像可识别病灶者不良病理和升级风险更高。
- 多参数磁共振成像有助于筛选适合主动监测的有利风险患者并指导活检与监测策略。
研究设计与样本
- 回顾性分析2010至2019年接受根治性前列腺切除术的有利风险2级组前列腺癌患者队列,共1117例。
- 术前多参数磁共振成像评分分为阴性(无可识别病灶)、阳性(可识别病灶)或不确定。
- 采用多变量逻辑回归模型,以多参数磁共振成像评分为预测因子、不良病理为结局,调整术前前列腺特异抗原、活检Gleason分级、临床分期及阴性和阳性活检针数。
主要发现
- 阳性多参数磁共振成像与不良病理相关(OR 2.55,95%CI 1.75-3.40,p<0.0001)。
- 阳性多参数磁共振成像与分级升级相关(OR 3.89,95%CI 2.00-7.56,p<0.0001)。
- 将多参数磁共振成像结果加入标准预测模型后,决策曲线分析显示净获益更高。
关键数值与推荐
- 不良病理定义为升级至T3a/b、升级至≥3级组或淋巴结侵犯。
临床怎么用
- 对有利风险2级组前列腺癌候选主动监测者,可结合多参数磁共振成像结果评估不良病理风险。
- 多参数磁共振成像信息可用于指导活检策略、治疗咨询及主动监测方案制定。
局限性
- 研究仅纳入接受根治性前列腺切除术的2级组患者,队列可能代表比整体2级组更高风险的人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The National Comprehensive Cancer Network® recommends that selected men with grade group 2 prostate cancer be considered for active surveillance. However, selecting which patients with grade group 2 disease can be safely managed by active surveillance remains controversial. The aim of this study was to evaluate the association of multiparametric magnetic resonance imaging with adverse pathology in the radical prostatectomy specimen of men with favorable risk grade group 2 prostate cancer, which could help select patients for active surveillance. MATERIALS AND METHODS: We retrospectively analyzed a cohort of patients with favorable grade group 2 disease who underwent radical prostatectomy between 2010 and 2019. Preoperative multiparametric magnetic resonance imaging was scored as negative (no identifiable lesion), positive (identifiable lesion) or equivocal. We defined a multivariable logistic regression model with multiparametric magnetic resonance imaging score as the predictor and adverse pathology (up staging to T3a/b disease, upgrading to ≥grade group 3 or lymph node invasion) as the outcome, adjusting for preoperative prostate specific antigen, biopsy Gleason grade, clinical stage, and number of negative and positive prostate biopsy cores. Secondary outcomes of biochemical recurrence, grade group upgrading alone and the added value of incorporating multiparametric magnetic resonance imaging data into the nomogram were also investigated. RESULTS: We identified 1,117 patients with favorable risk grade group 2 disease who underwent radical prostatectomy. Positive multiparametric magnetic resonance imaging was associated with higher rates of adverse pathology (OR 2.55, 95% CI 1.75-3.40, p <0.0001) and upgrading (OR 3.89, 95% CI 2.00-7.56, p <0.0001). However, as our study included only grade group 2 patients who underwent radical prostatectomy, our cohort may represent a higher risk group than grade group 2 patients as a whole. Adding multiparametric magnetic resonance imaging results to a standard prediction model led to higher net benefit on decision curve analysis. An identifiable lesion on multiparametric magnetic resonance imaging was associated with an increased risk of aggressive pathological features in the radical prostatectomy specimen of patients with favorable risk grade group 2 prostate cancer who were potential active surveillance candidates. This information could be used to inform biopsy strategy, counsel patients on treatment options and guide strategies for those on active surveillance. CONCLUSIONS: Combining multiple magnetic resonance imaging modalities (multiparametric magnetic resonance imaging) provides a more accurate prediction of the risk presented by prostate cancer than current prediction methods. In this study, positive magnetic resonance imaging results approximately doubled the chances that a patient with favorable risk prostate cancer would be found to have adverse pathology when their prostate was removed. Thus, multiparametric magnetic resonance imaging could help select patients with favorable risk cancer who may be good candidates for active surveillance, and help guide biopsy and surveillance strategies for such patients.
引用
- Stonier T, Tin AL, Sjoberg DD, et al. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? J Urol. 2020. PMID: 33216696. doi:10.1097/JU.0000000000001519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。